Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30, 2010 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30January 1, 2010 2011 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30July 15, 2010 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30, 2010 within one hundred eighty (the “Assignment Deadline”)180) days after closing of Financing Round A, both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadlineend of such one hundred eighty (180) days period.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30November 1, 2010 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30July 1, 2010 2011 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)
Section 12. 1. The third sentence in Section 12.1 is hereby amended as follows: “In case such take over of the Supply Agreement Relating To Supply Of A OMEGA-3 Fatty Acid Concentrate (Omefas®) in Annex C will not take place on or prior to September 30March 1, 2010 2011 (the “Assignment Deadline”), both Parties shall have the right to early terminate the Agreement (see Section 19.2b) within thirty (30) days after the Assignment Deadline.”
Appears in 2 contracts
Sources: License Agreement (Omthera Pharmaceuticals, Inc.), License Agreement (Omthera Pharmaceuticals, Inc.)